Oral Solid Dosage Contract Manufacturing Market Grows Amid Personalized Medicine Trends

The oral solid dosage (OSD) contract manufacturing market is undergoing a significant transformation, driven by the increasing demand for personalized medicine and the growing complexities of pharmaceutical development. As pharmaceutical companies strive to meet diverse patient needs, enhance treatment efficacy, and reduce costs, they are increasingly turning to contract manufacturing organizations (CMOs) specializing in OSD forms. Tablets, capsules, powders, and granules continue to dominate the pharmaceutical landscape due to their stability, convenience, and patient compliance, and CMOs are evolving rapidly to offer flexible, scalable, and customized solutions that align with the precision healthcare movement. The rise of personalized medicine, which emphasizes tailoring treatment to individual patient profiles, has introduced new variables into drug formulation and production. This shift is not only reshaping product development strategies but also opening new avenues of growth for OSD contract manufacturers.

The global oral solid dosage contract manufacturing market size is anticipated to rise from US$ 38 Bn in 2025 to US$ 57.9 Bn by 2032. It is projected to witness a CAGR of 6.2% from 2025 to 2032. Advancements in drug delivery technology, including targeted dosage forms and 3D printing, are transforming the oral pharmaceuticals market, improving patient outcomes and ensuring precise dosage control.

The Importance of Oral Solid Dosage Forms in Modern Pharmaceuticals

• Widespread Use and Acceptance

OSD forms such as tablets and capsules are the most common forms of drug delivery due to their ease of administration, extended shelf life, and cost-effectiveness. Their wide acceptability among patients across age groups and demographics makes them an essential part of pharmaceutical development pipelines.

• Advantages in Storage and Transport

Compared to liquid or injectable forms, OSD products are easier to store, more stable under varied environmental conditions, and simpler to transport, making them ideal for global distribution and supply chain efficiency.

• Formulation Flexibility

OSD formulations allow for controlled release, extended release, and immediate release capabilities, enabling manufacturers to align drug delivery profiles with therapeutic goals. This flexibility makes them suitable for both generic and specialty drugs.

Personalized Medicine as a Growth Driver

• Tailored Therapeutics for Better Outcomes

Personalized medicine seeks to optimize treatment outcomes by considering genetic, environmental, and lifestyle factors unique to each patient. OSD forms, when customized to patient profiles, allow for precise dosing and targeted drug delivery, enhancing therapeutic effectiveness.

• Growth in Orphan Drugs and Specialty Medicines

The rising demand for rare disease treatments and specialty pharmaceuticals often requires low-volume, high-complexity manufacturing, which many pharma companies outsource to specialized OSD CMOs to manage cost and expertise constraints.

• Shift from Mass Production to Micro Batches

The personalized approach demands smaller batch sizes and more frequent production runs with different specifications. CMOs that can accommodate this shift through modular manufacturing and agile operations are seeing increased demand.

Why Pharma Companies Prefer OSD Contract Manufacturers

• Cost Savings and Operational Efficiency

Outsourcing OSD manufacturing helps pharmaceutical companies reduce capital expenditure on facilities, equipment, and regulatory compliance. CMOs provide economies of scale and process expertise, translating to lower costs and faster time to market.

• Focus on Core Competencies

Pharma companies are focusing their internal resources on drug discovery, clinical research, and marketing, while leaving complex manufacturing tasks to experienced partners. This separation of roles enhances overall productivity and innovation.

• Regulatory Compliance and Quality Assurance

Reputed CMOs invest heavily in maintaining GMP-compliant facilities, updated quality management systems, and global regulatory certifications. This reduces the regulatory burden on pharma companies and ensures product integrity and safety.

• Technological Advancements and Process Optimization

Modern OSD CMOs utilize advanced technologies such as continuous manufacturing, process analytical technology (PAT), and digital batch records, allowing for greater efficiency, traceability, and quality control.

Trends Reshaping the OSD Contract Manufacturing Landscape

• Adoption of Continuous Manufacturing

Continuous manufacturing allows uninterrupted production, reducing cycle times and improving batch consistency. It also supports personalized production with its capacity for fast changeovers and scalability.

• Integration of Digital Tools and Automation

Smart manufacturing, powered by IoT, AI, and robotics, is becoming central to OSD production. These technologies help in predictive maintenance, real-time monitoring, and automated quality control, driving operational excellence.

• Expansion of High Potency and Modified Release Products

With the growing demand for oncology drugs and therapeutics requiring targeted delivery, CMOs are investing in capabilities to handle high-potency active pharmaceutical ingredients (HPAPIs) and complex modified-release formulations.

• Green Manufacturing and Sustainability Focus

OSD CMOs are increasingly adopting sustainable practices such as solvent recycling, waste minimization, and energy-efficient systems, reflecting the industry's commitment to environmental responsibility.

• Enhanced Customization Capabilities

To cater to the needs of personalized medicine, CMOs are improving their ability to deliver customized dosage forms, varying strengths, and different combinations with precision and consistency.

Applications and End-User Segments Fueling Demand

• Generic Drug Manufacturers

The generic pharmaceutical segment, driven by patent expirations and cost-conscious healthcare systems, heavily relies on CMOs for large-scale, cost-effective OSD production.

• Biopharma and Specialty Drug Companies

Small and medium-sized biotech companies, often lacking in-house manufacturing capabilities, outsource OSD production to CMOs to speed up commercialization of their innovative therapies.

• Large Pharmaceutical Corporations

Even big pharma companies with existing infrastructure choose to outsource OSD production for specific markets, specialty drugs, or to meet surge demands efficiently.

• Over-the-Counter (OTC) Product Providers

The OTC segment, encompassing vitamins, supplements, and common medications, leverages OSD CMOs to manufacture vast volumes with consistent quality and regulatory compliance.

Challenges Hindering Market Expansion

• Complex Regulatory Environment

OSD CMOs must navigate diverse regulatory frameworks across geographies. Keeping up with evolving requirements from agencies like the FDA, EMA, and others demands continuous investment in compliance infrastructure.

• Capacity and Capability Mismatches

Surging demand for customized solutions can lead to capacity constraints. Not all CMOs are equipped to handle complex formulations or specialized production needs, limiting client options.

• Data Security and Intellectual Property Concerns

Outsourcing involves sharing sensitive data and proprietary information. Ensuring secure data management and IP protection is critical to building trust between pharma companies and CMOs.

• Quality Consistency Across Batches

Maintaining consistent quality in micro-batches for personalized medicine can be challenging. CMOs must invest in precision systems and validation protocols to uphold standards.

• Integration with Pharma Workflows

Efficient coordination between the pharma company and the CMO is essential for successful production. Misalignment in timelines, documentation, or technology can result in delays and added costs.

Opportunities Driving Future Market Expansion

• Growth in Emerging Markets

Rising healthcare investments and demand for affordable medicines in regions like Asia-Pacific, Latin America, and the Middle East are creating lucrative opportunities for OSD CMOs to expand their global footprint.

• Increased Demand for Pediatric and Geriatric Formulations

As personalized medicine includes age-specific treatments, there is a growing need for easy-to-swallow tablets, flavored chewables, and mini tablets tailored for children and elderly populations.

• Development of 3D Printed Tablets

Innovations in 3D printing offer the ability to create personalized tablets with customized drug release profiles. CMOs integrating such technologies are positioned to lead the next wave of OSD manufacturing.

• Biosimilars and Combination Therapies

While biologics dominate innovation, biosimilar and fixed-dose combination therapies in oral forms are gaining ground. CMOs with formulation expertise in these areas can capitalize on the growing demand.

• Partnerships and Strategic Collaborations

Collaborative ventures between CMOs and pharma companies, research institutions, or technology providers will facilitate knowledge sharing, risk management, and the development of next-gen oral formulations.

Regional Highlights and Market Hotspots

• North America Leads in Advanced Manufacturing

North America, particularly the U.S., holds a significant share of the OSD CMO market due to its strong pharmaceutical base, advanced infrastructure, and focus on high-quality standards and innovation.

• Europe Focuses on High-Value OSD Products

European CMOs are recognized for their expertise in niche formulations, sustained-release tablets, and compliance with stringent EU regulations, making them reliable partners for complex OSD needs.

• Asia-Pacific Emerges as a Cost-Effective Hub

Countries like India and China offer cost-efficient manufacturing with skilled labor and a growing ecosystem of FDA- and WHO-compliant facilities, attracting global pharma companies to outsource production.

• Middle East and Africa Witness Rising Demand

With growing healthcare access and chronic disease burden, the demand for generic OSD drugs and localized production in these regions is rising, encouraging investments in manufacturing capabilities.

Future Outlook: A Personalized Yet Scalable Market

• Dynamic Growth Trajectory

The OSD contract manufacturing market is poised for continued expansion as precision medicine becomes mainstream. Flexibility, speed, and quality will define the success of CMOs in the coming years.

• Investments in Technology and Talent

CMOs will need to enhance their technological capabilities and build specialized teams to meet the complexities of customized OSD production. Innovation and skilled labor will be key differentiators.

• Strategic Supply Chain Optimization

To support personalized medicine, CMOs will focus on lean supply chains, just-in-time delivery, and close integration with pharma partners to ensure efficient and responsive production cycles.

• Enhanced Role in Drug Development

Beyond manufacturing, CMOs are increasingly involved in formulation development, regulatory consulting, and lifecycle management, making them strategic partners in the drug development value chain.

• Patient-Centric Manufacturing Approach

As the industry shifts from volume-centric to value-centric manufacturing, CMOs that prioritize patient needs and therapeutic effectiveness will become vital players in the healthcare ecosystem.

Conclusion

The convergence of personalized medicine with oral solid dosage forms is reshaping the pharmaceutical manufacturing landscape. As pharmaceutical companies face increasing complexity in drug development, the need for specialized, agile, and quality-focused manufacturing partners has never been more critical. Oral solid dosage CMOs are stepping up to this challenge by offering advanced solutions that meet the demands of precision healthcare. With ongoing technological advancements, expanding global reach, and rising demand for customized treatments, the oral solid dosage contract manufacturing market is set to thrive. The future belongs to CMOs that combine scientific excellence with operational agility to deliver safe, effective, and personalized therapies to patients around the world.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐋𝐚𝐭𝐞𝐬𝐭 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 "𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞”:

• https://www.openpr.com/news/4034295/interventional-oncology-market-growth-accelerates-toward

• https://www.openpr.com/news/4034296/vagus-nerve-stimulation-market-valuation-to-hit-us-783-1

• https://www.openpr.com/news/4034298/atrial-fibrillation-devices-market-shows-strong-growth

• https://www.openpr.com/news/4034298/atrial-fibrillation-devices-market-shows-strong-growth

• https://www.openpr.com/news/4034300/medicated-skincare-market-climbs-to-us-36-7-billion-in-2024

• https://www.openpr.com/news/4034874/ultrasonic-flow-meter-market-set-for-substantial-growth

• https://www.openpr.com/news/4034890/shell-tube-heat-exchanger-market-predicted-to-grow